CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.

CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.

BACKGROUND: Chemoresistance is the main obstacle to cure in most malignant diseases. Anthracyclines are among the main drugs used for breast cancer therapy and in many other malignant conditions. Single parameter analysis or global gene expression profiles have failed to identify mechanisms causing...

Full description

Bibliographic Details
Main Authors: Ranjan Chrisanthar, Stian Knappskog, Erik Løkkevik, Gun Anker, Bjørn Østenstad, Steinar Lundgren, Elisabet O Berge, Terje Risberg, Ingvil Mjaaland, Lovise Maehle, Lars Fredrik Engebretsen, Johan Richard Lillehaug, Per Eystein Lønning
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2008-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC2518116?pdf=render

Similar Items

Similar Items